Top Markets
#1 Akedo Akedo +85.57%
#2 TENDIES TENDIES +76.85%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.83%
#5 Mubarak Mubarak +30.39%
#6 MultiversX MultiversX +28.68%
#7 Bitway Bitway +24.57%
#8 Cash Cat Cash Cat +23.24%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rank in Stocks #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)

Category

Healthcare
P/B ratio for Regulus Therapeutics Inc. (RGLS)
P/B ratio as of September 2026 TTM: 6.02
According to Regulus Therapeutics Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 6.02. At the end of 2023 the company had a P/B ratio of 1.15.
P/B ratio history for Regulus Therapeutics Inc. from 2010 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 6.02 414.32%
2024 1.17 1.71%
2023 1.15 82.40%
2022 0.63 25.85%
2021 0.50 -72.50%
2020 1.81 136.39%
2019 0.77 -155.41%
2018 -1.39 -145.10%
2017 3.07 44.92%
2016 2.12 -41.35%
2015 3.61 -32.55%
2014 5.36 76.06%
2013 3.04 265.18%
2012 0.83 -3,304.62%
2011 -0.03 -119.29%
2010 0.13 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.828 13.47%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.5116 24.83%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.2199 36.60%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9942 -33.62%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH